Supernus Pharmaceuticals Reports Q3 2026 Revenue Growth and Raises Full-Year Guidance
Supernus Pharmaceuticals (SUPN) reported strong third-quarter 2026 financial results, highlighted by an 18% year-over-year increase in total revenue to $226.8 million. The growth was primarily driven by its product portfolio, with Qelbree net sales reaching $90.8 million and ZURZUVAE collaboration revenue contributing $41.7 million. Notably, the company swung from a net loss in the prior year's third quarter to a GAAP net earning of $20.9 million. Following shareholder approval on October 15, 2026, the company is set to finalize its merger with Indivior Pharmaceuticals on November 2, 2026. Management expects the integration to yield $125 million in annual cost synergies. Due to this upcoming transition, Supernus raised its full-year 2026 revenue and non-GAAP operating earnings guidance for the stand-alone entity, though these figures will be superseded once the merger is complete.
Topics: Net Income Pharmaceuticals Product Sales Revenue Growth